NCT05833971View on ClinicalTrials.gov

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2026

Conditions

Resectable Esophageal Squamous Cell CarcinomaNeoadjuvant Therapy

Interventions

DRUG

cadonilimab+chemotherapy

cadonilimab plus cisplatin and Nab-PTX, Q3W

All Listed Sponsors

lead

Guangzhou Institute of Respiratory Disease

OTHER